Significance of High Density Lipoprotein-Cholesterol in Cardiovascular Risk Prevention
Autor: | Antonio Hernández Mijares, Jesús Millán, Arturo Fernández-Cruz, Juan F. Ascaso, Juan Rubiés-Prat, Pedro González Santos, Gonzalo Pía, Francisco Pérez-Jiménez, Xavier Pintó, Luis Felipe Pallardo, Juan Pedro-Botet, Ignacio Plaza, Alipio Mangas Rojas |
---|---|
Rok vydání: | 2004 |
Předmět: |
medicine.medical_specialty
Cholesterol business.industry Hypertriglyceridemia Reverse cholesterol transport nutritional and metabolic diseases Type 2 Diabetes Mellitus General Medicine Disease Bioinformatics medicine.disease chemistry.chemical_compound Endocrinology High-density lipoprotein chemistry Internal medicine medicine lipids (amino acids peptides and proteins) Pharmacology (medical) Metabolic syndrome Cardiology and Cardiovascular Medicine business Risk assessment |
Zdroj: | American Journal of Cardiovascular Drugs. 4:299-314 |
ISSN: | 1175-3277 |
DOI: | 10.2165/00129784-200404050-00003 |
Popis: | In the approach to lipid-related risk factors for cardiovascular diseases, serum high density lipoprotein-cholesterol (HDL-C) levels bear a particular significance as this lipoprotein is considered to be an antiatherogenic factor mainly, but not only, because of its influence and impact on reverse cholesterol transport. Hence the need and requirement to consider serum HDL-C levels for both primary and secondary prevention of cardiovascular disease. A particularly important aspect is the association of the 'low HDL syndrome' with the metabolic syndrome. These factors force us to consider serum HDL-C level as a therapeutic target by itself, or even in association with low density lipoprotein-cholesterol (LDL-C) levels when the latter are increased. This review stresses the aspects connecting serum HDL-C levels and cardiovascular risk, and looks at the populations that should be considered amenable to therapeutic management because of low serum HDL-C levels. We review therapeutic strategies, both pharmacological and nonpharmacological. The aim of this review is to present therapeutic management recommendations for correcting the proportion of cardiovascular risk that is attributable to changes in HDL-C. Serum HDL-C levels of >40 mg/dL must be a therapeutic target in primary and secondary prevention. This goal is particularly important in patients with low serum HDL-C levels and ischemic heart disease (IHD) or its equivalents, even if the therapeutic target for serum LDL-C levels ( 20%), hypertriglyceridemia, type 2 diabetes mellitus, or metabolic syndrome. |
Databáze: | OpenAIRE |
Externí odkaz: |